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coronary occlusions. Am J Cardiol 2008;101:179–85.HDL-C and MortalityKo et al. conclude (1) that “high-density lipoprotein
cholesterol (HDL-C) level is unlikely to represent a
cardiovascular risk factor or a target for intervention.”
As this has profound implications, I’d like to discuss
possible explanations behind their ﬁndings. Alcohol
intake increases total HDL-C, and therefore HDL-C is
in part a measure of alcohol intake. High non–cardio-
vascular disease mortality at very high HDL-C levels
may well be due to alcohol-induced non–cardiovas-
cular disease mortality. I showed in a prospective
population study (the KIHD [Kuopio Ischemic Heart
Disease] study) in Finland that low HDL-C is associ-
ated with increased coronary, cardiovascular, and all-
cause mortality only if alcohol intake, as measured by
serum gamma–glutamyl transferase levels, is low (2). I
suggested in my discussion that HDL elevation might
be beneﬁcial only if gamma–glutamyl transferase is
low and promoted liver enzyme measurements in
studies of HDL-C and mortality. Therefore, I question
the validity of the authors’ conclusions, which were
based on a study with no data on either alcohol intake
or liver damage.*Jukka T. Salonen, MD, PhD, MSc
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cholesterol. BMJ 2003;327:1082–3.REPLY: HDL-C and MortalityWe appreciate the comments raised by Dr. Salonen
regarding the potential role of alcohol on our results.
Dr. Salonen suggests that the relationship between
high-density lipoprotein (HDL) cholesterol and out-
comes may be discordant based on alcohol intake or
liver enzyme levels (1).
In our study, we evaluated more than 630,000
individuals without prior cardiovascular conditions
(2). We were able to impute alcohol use in the cohort
using data from the Canadian Community Health
Survey (CCHS), an ongoing Canada-wide population-
based survey that collected information on self-
reported health behavior. We found that 12.5% of
individuals had heavy alcohol consumption (deﬁned
as $5 drinks on 12 occasions per year).
The evaluation of the independent association of
HDL-cholesterol (HDL-C) level and cause-speciﬁc
mortality was conducted by adjusting for liver dis-
ease (identiﬁed using administrative database codes),
heavy alcohol consumption (imputed from the CCHS),
demographics, and comorbidities. We found that in-
dividuals with lower HDL-C levels had increased
hazard of cardiovascular deaths, cancer deaths, and
noncardiovascular noncancer deaths. In addition, we
also observed individuals who had very high HDL-C
levels had increased hazard of noncardiovascular
deaths. We agree that future research into reasons
underlying higher noncardiovascular deaths among
individuals with very high HDL-C levels is warranted
and that alcohol intake could be an important
contributor. In light of the inability of randomized
trials to improve clinical outcomes by increasing
HDL-C levels (3), and a Mendelian study showing no
reduced clinical risk with genetic mechanism that
raise HDL-C levels (4), our study adds to the existing
